Fake news. Wrong place to look at. Here is the evidence.
Remestemcel-L is application to Center for Biologics Evaluation and Research (CBER).
https://www.fda.gov/media/141131/download
The page "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page" is for Center for Drug Evaluation and Research (CDER).
If you click on search this month you will find this line:
"Drug Approval Reports by MonthSelect a Report:Reports include only BLAs/NDAs/ANDAs or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER)."
https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2020-biological-device-application-approvals is the latest CBER approvals.
- Forums
- ASX - By Stock
- MSB officially rejected?
Fake news. Wrong place to look at. Here is the...
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.03 |
Change
-0.025(2.38%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.06 | $1.06 | $1.02 | $5.734M | 5.571M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 203347 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 125348 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 203347 | 1.020 |
12 | 412127 | 1.015 |
12 | 92894 | 1.010 |
6 | 80671 | 1.005 |
27 | 111616 | 1.000 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 125348 | 6 |
1.035 | 96469 | 8 |
1.040 | 25000 | 2 |
1.045 | 31585 | 4 |
1.050 | 70234 | 5 |
Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.03 |
  |
Change
-0.025 ( 2.94 %) |
|||
Open | High | Low | Volume | ||
$1.06 | $1.06 | $1.02 | 953870 | ||
Last updated 15.59pm 16/05/2024 ? |
Featured News
MSB (ASX) Chart |